Related Experiment Video
Updated: Apr 4, 2026

A Web Tool for Generating High Quality Machine-readable Biological Pathways
Published on: February 8, 2017
Incorporation of Biological Pathway Knowledge in the Construction of Priors for Optimal Bayesian Classification
Abstract:
Small samples are commonplace in genomic/proteomic classification, the result being inadequate classifier design and poor error estimation. The problem has recently been addressed by utilizing prior knowledge in the form of a prior distribution on an uncertainty class of feature-label distributions. A critical issue remains: how to incorporate biological knowledge into the prior distribution. For genomics/proteomics, the most common kind of knowledge is in the form of signaling pathways. Thus, it behooves us to find methods of transforming pathway knowledge into knowledge of the feature-label distribution governing the classification problem. In this paper, we address the problem of prior probability construction by proposing a series of optimization paradigms that utilize the incomplete prior information contained in pathways (both topological and regulatory). The optimization paradigms employ the marginal log-likelihood, established using a small number of feature-label realizations (sample points) regularized with the prior pathway information about the variables. In the special case of a Normal-Wishart prior distribution on the mean and inverse covariance matrix (precision matrix) of a Gaussian distribution, these optimization problems become convex. Companion website: gsp.tamu.edu/Publications/supplementary/shahrokh13a.
Related Concept Videos
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Phylogenetic Trees
Evolutionary Relationships through Genome Comparisons
Applications of Molecular Taxonomy
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Model Approaches for Pharmacokinetic Data: Physiological Models

